ATAI
AtaiBeckley·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ATAI
Ataibeckley Inc.
A clinical-stage biopharmaceutical company that developing treatment for mental health disorders
c/o atai Life Sciences US, Inc., c/o Industrious NYC, 250 West 34th Street, New York, NY 10119
--
AtaiBeckley Inc., was incorporated under the laws of the Netherlands on September 10, 2020. On January 11, 2021, it was renamed ATAI Life Sciences B.V. On November 5, 2025, it was renamed Atai Beckley N.V. On January 2, 2026, the company name was changed to AtaiBeckley Inc., and it was transformed into a company incorporated under the laws of the State of Delaware. AtaiBeckley Inc., a clinical-stage biopharmaceutical company, develops highly effective mental health therapies to improve patient outcomes. The company is advancing the development of a range of product candidates designed to address the complexity of mental health disorders.
Company Financials
EPS
ATAI has released its 2025 Q3 earnings. EPS was reported at -0.28, versus the expected -0.11, missing expectations. The chart below visualizes how ATAI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ATAI has released its 2025 Q3 earnings report, with revenue of 749.00K, reflecting a YoY change of 1772.50%, and net profit of -61.10M, showing a YoY change of -132.21%. The Sankey diagram below clearly presents ATAI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
